8,335 Shares in Colgate-Palmolive Company $CL Purchased by Summit Wealth Group LLC Co.

Posted by Francis Steltz on Nov 4th, 2026

Summit Wealth Group LLC Co. purchased a new stake in Colgate-Palmolive Company (NYSE:CL – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 8,335 shares of the company’s stock, valued at approximately $711,000.

A number of other institutional investors have also recently added to or reduced their stakes in CL. Cooper Financial Group raised its position in Colgate-Palmolive by 4.0% during the second quarter. Cooper Financial Group now owns 2,947 shares of the company’s stock worth $270,000 after acquiring an additional 114 shares during the period. Gould Capital LLC lifted its holdings in Colgate-Palmolive by 38.7% during the first quarter. Gould Capital LLC now owns 412 shares of the company’s stock valued at $35,000 after purchasing an additional 115 shares in the last quarter. Redhawk Wealth Advisors Inc. lifted its holdings in Colgate-Palmolive by 2.8% during the second quarter. Redhawk Wealth Advisors Inc. now owns 4,326 shares of the company’s stock valued at $397,000 after purchasing an additional 118 shares in the last quarter. SVB Wealth LLC grew its position in shares of Colgate-Palmolive by 1.4% in the second quarter. SVB Wealth LLC now owns 8,767 shares of the company’s stock valued at $804,000 after purchasing an additional 119 shares during the period. Finally, Sowell Financial Services LLC grew its position in shares of Colgate-Palmolive by 2.1% in the third quarter. Sowell Financial Services LLC now owns 5,737 shares of the company’s stock valued at $490,000 after purchasing an additional 119 shares during the period. Institutional investors and hedge funds own 80.41% of the company’s stock.

Insider Buying and Selling

In other Colgate-Palmolive news, Director John Cahill sold 4,170 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total value of $389,352.90. Following the transaction, the director directly owned 28,373 shares of the company’s stock, valued at $2,649,187.01. This trade represents a 12.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Panagiotis Tsourapas sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $92.05, for a total value of $920,500.00. Following the transaction, the chief operating officer owned 64,901 shares in the company, valued at approximately $5,974,137.05. This represents a 13.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.43% of the company’s stock.

Colgate-Palmolive Price Performance

Shares of NYSE CL opened at $95.36 on Wednesday. The firm has a 50-day simple moving average of $89.73 and a 200-day simple moving average of $89.77. The stock has a market capitalization of $75.80 billion, a price-to-earnings ratio of 37.40, a price-to-earnings-growth ratio of 4.55 and a beta of 0.31. The company has a quick ratio of 0.30, a current ratio of 0.96 and a debt-to-equity ratio of 11.23. Colgate-Palmolive Company has a 52 week low of $75.00 and a 52 week high of $99.33.

Colgate-Palmolive (NYSE:CL – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.34 billion. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the firm posted $0.91 earnings per share. On average, equities analysts predict that Colgate-Palmolive Company will post 3.91 earnings per share for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th will be issued a $0.53 dividend. The ex-dividend date is Tuesday, October 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.2%. Colgate-Palmolive’s dividend payout ratio is presently 83.14%.

Key Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

Positive Sentiment: Colgate-Palmolive beat third-quarter estimates, with sales up 4.6% year over year, and raised its EPS outlook while narrowing its 2026 sales outlook. Management cited resilient global demand and premium innovation, although costs remain a pressure. Q3 deep dive
Positive Sentiment: Several analysts raised their targets after the results. Morgan Stanley lifted its target to $111 and kept an overweight rating; BNP Paribas Exane raised its target to $108 and reaffirmed outperform; RBC raised its target to $105 and maintained outperform. Analyst forecasts after Q3 earnings
Neutral Sentiment: JPMorgan trimmed its target to $102 but retained an overweight rating. Barclays and Wells Fargo raised their targets to $95 while keeping equal-weight ratings, signaling limited upside at those firms’ estimates.
Negative Sentiment: A valuation comparison noted that Colgate-Palmolive trades at a higher forward price-to-earnings multiple than Lululemon, raising questions about whether CL’s premium valuation is justified. Valuation comparison

Analyst Ratings Changes

CL has been the subject of several research analyst reports. Piper Sandler reduced their price target on shares of Colgate-Palmolive from $98.00 to $95.00 and set an “overweight” rating for the company in a research report on Monday, September 21st. TD Cowen lifted their price objective on Colgate-Palmolive from $90.00 to $97.00 and gave the stock a “hold” rating in a report on Monday. UBS Group lifted their price objective on Colgate-Palmolive from $106.00 to $112.00 and gave the stock a “buy” rating in a report on Monday. Citigroup boosted their price objective on Colgate-Palmolive from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Evercore increased their target price on Colgate-Palmolive from $100.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $101.22.

View Our Latest Stock Analysis on CL

Colgate-Palmolive Profile

(Free Report)

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.